Presentation of European IP Helpdesk on IP in Biotech
Bookmark this resource
EU IP HD Webinar- Consortium Agreements
Published by European Commission (EC)
CoursesTrainingWebinars
Published by European Commission (EC)
CoursesTrainingWebinarsPresentation of European IP Helpdesk on IP in Biotech
Bookmark this resourcePublished by European Commission (EC)
CoursesTrainingWebinarsPresentation of European IP Helpdesk on IP in Biotech
Bookmark this resourceIt is a common practice for the company to conduct a Freedom to Operate (FTO) search to determine and reduce the risks of potential patent infringement prior to launching a new product or service. The FTO search is performed to find relevant third parties’ patents that may cover the new product or service. The FTO is also called “Patent Clearance”. If the company completely neglects the FTO search, and then, later on, the product is found to infringe a third parties’ patent, it is most likely that the company would be sued by the patentee as an infringement of the patent.
Bookmark this resourcePublished by European Commission (EC)
CoursesTrainingWebinarsPresentation of European IP Helpdesk on IP in Biotech
Bookmark this resourcePresentation of European IP Helpdesk on IP Assessment
Bookmark this resourcePublished by European Commission (EC)
CoursesTrainingWebinarsPresentation of European IP Helpdesk on Patent_Protection_for_EU_funding – Medical Technologies
Bookmark this resourcePublished by European Medicines Agency (EMA)
Drug DevelopmentEMAGuidelinePharmaceuticalsThis guidance is for qualification process addresses innovative drug development methods and tools. It will focus on the use of novel methodologies developed by consortia, networks, public/private partnerships, learned societies and pharmaceutical industry for a specific intended use in pharmaceuticals R&D.
View this resource Bookmark this resourcePublished by European Medicines Agency (EMA)
Animal ModelsClinical TrialsEMAGuidelinePharmaceuticals ToxicityVaccineThis guideline applies to all pharmaceuticals, including biopharmaceuticals, vaccines (and their novel constitutive ingredients) for infectious diseases, and novel excipients that are part of the final pharmaceutical product.
View this resource Bookmark this resourcePublished by EMA
Gene TherapyMedical ProductsNon-Clinical Development ChecklistEMA’s guide to help developers of gene therapy medicinal products (GTMPs) and cell-based medicinal products (CBMPs) navigate the most important regulatory requirements during the non-clinical development phase
View this resource Bookmark this resourcePublished by European Commission (EC)
Commission DirectiveHuman Tissues and CellsThis Directive amends the Directive 2006/86/EC as regards certain technical requirements for the coding of human tissues and cells
View this resource Bookmark this resource